HIV and mitochondrial toxicity in children

Area of Science:

• Pediatric HIV/AIDS
• Mitochondrial Toxicology
• Pharmacology

Background:

• Combination antiretroviral (ARV) therapy has dramatically reduced pediatric HIV mortality and mother-to-child transmission (MTCT).
• Prolonged ARV exposure in children necessitates understanding cumulative toxicities, particularly mitochondrial effects from nucleoside reverse transcriptase inhibitors (NRTIs).

Purpose of the Study:

• To review the evidence and proposed mechanisms of NRTI-associated mitochondrial toxicity in children with HIV-1 infection.
• To discuss the implications of NRTI exposure for both infected children and uninfected infants exposed during MTCT prevention.
• To highlight the urgent need for pediatric studies evaluating reduced NRTI exposure or alternative NRTIs with lower toxicity.

Main Methods:

• Review of in vitro, animal model, and human clinical data on NRTI mitochondrial toxicity.
• Analysis of clinical presentations of NRTI-associated mitochondrial dysfunction in children.
• Discussion of ongoing controversies regarding mitochondrial effects in NRTI-exposed children.

Main Results:

• Evidence suggests NRTIs can impair mitochondrial DNA replication and cause point mutations, leading to mitochondrial dysfunction.
• Clinical manifestations in children include lactic acidosis, pancreatitis, cardiomyopathy, and neuropathy.
• Animal models show mitochondrial toxicity from perinatal NRTI exposure, but effects in exposed children remain debated.

Conclusions:

• Minimizing NRTI-associated toxicities is crucial given expanding ARV treatment options.
• Further pediatric research is essential to guide safer NRTI use and inform treatment strategies.
• Developing ARVs with reduced mitochondrial toxicity is a growing necessity in pediatric HIV care.